Key Takeaways
- • Private equity healthcare deal volume and value declined in the first half of 2026 compared to the same period in 2025, according to PitchBook data, signaling regulatory headwinds are impacting transaction activity.
- • At least 25 states have proposed or enacted laws tightening oversight of healthcare transactions, with California, Oregon, and Rhode Island implementing new regulations in 2026 requiring enhanced documentation and transparency on mergers and acquisitions.
- • State-level regulatory frameworks are restricting non-physician-controlled companies and private equity operators from acquiring medical practices, while mandating longer timelines and higher compliance costs for deal closure.
- • Private equity healthcare investment has surged dramatically from $5 billion in 2000 to an estimated $104 billion in 2024, making legislative scrutiny increasingly aggressive as lawmakers debate whether PE involvement drives up care costs and harms patient access.
- • Research indicates physician practices acquired by private equity between 2016 and 2020 saw price increases of 11% and volume increases of 16% post-acquisition, fueling policy concerns about affordability and consolidation risks.
Summary
State-level regulatory momentum is materially constraining private equity's healthcare investment pipeline. According to PitchBook analysis released in September 2026, both the number and aggregate value of PE-backed healthcare deals have contracted year-over-year, with first-half 2026 transaction values trailing the comparable 2025 period. The deceleration directly correlates with a wave of state legislation designed to slow healthcare industry consolidation by private capital.
At least 25 states have either proposed or enacted new oversight laws governing healthcare M&A activity in recent years. Three states—California, Oregon, and Rhode Island—implemented new regulatory regimes during 2026 specifically requiring heightened documentation, transparency requirements, and government review for healthcare mergers, acquisitions, and related transactions. Rhode Island Attorney General Peter Neronha, in announcing his state's new regulatory framework in January 2026, explicitly framed the oversight as necessary to prevent private equity and market consolidation from driving up care costs and restricting patient access to services. These laws impose material friction on deal execution by mandating extended review periods and increased compliance costs.
The legislative response reflects growing concern about private equity's scale and operational model in healthcare. PE investment in the sector expanded dramatically from $5 billion in 2000 to $104 billion in 2024—a more than 20-fold increase over two decades. Academic research has documented that physician practices acquired by private equity firms between 2016 and 2020 exhibited price increases of 11% and volume increases of 16% in the post-acquisition period, lending empirical weight to policymaker concerns about the relationship between PE ownership and rising healthcare costs.
The new state regulatory framework directly targets PE operational strategies by restricting non-physician-led entities from controlling medical practices and limiting PE firms' consolidation capacity—a core value-creation lever in PE playbooks. PitchBook analysts identified that state-level restrictions are making healthcare acquisitions and roll-up strategies demonstrably slower and more expensive to execute. Lawmakers remain divided on whether private equity bears responsibility for systemic healthcare cost inflation and access challenges, but the regulatory trajectory at the state level suggests increased friction ahead for deal-making activity in the sector.
At least 25 states have either proposed or enacted new oversight laws governing healthcare M&A activity in recent years. Three states—California, Oregon, and Rhode Island—implemented new regulatory regimes during 2026 specifically requiring heightened documentation, transparency requirements, and government review for healthcare mergers, acquisitions, and related transactions. Rhode Island Attorney General Peter Neronha, in announcing his state's new regulatory framework in January 2026, explicitly framed the oversight as necessary to prevent private equity and market consolidation from driving up care costs and restricting patient access to services. These laws impose material friction on deal execution by mandating extended review periods and increased compliance costs.
The legislative response reflects growing concern about private equity's scale and operational model in healthcare. PE investment in the sector expanded dramatically from $5 billion in 2000 to $104 billion in 2024—a more than 20-fold increase over two decades. Academic research has documented that physician practices acquired by private equity firms between 2016 and 2020 exhibited price increases of 11% and volume increases of 16% in the post-acquisition period, lending empirical weight to policymaker concerns about the relationship between PE ownership and rising healthcare costs.
The new state regulatory framework directly targets PE operational strategies by restricting non-physician-led entities from controlling medical practices and limiting PE firms' consolidation capacity—a core value-creation lever in PE playbooks. PitchBook analysts identified that state-level restrictions are making healthcare acquisitions and roll-up strategies demonstrably slower and more expensive to execute. Lawmakers remain divided on whether private equity bears responsibility for systemic healthcare cost inflation and access challenges, but the regulatory trajectory at the state level suggests increased friction ahead for deal-making activity in the sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.